NasdaqCM:MOTS

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Motus GI Holdings, Inc., medical technology company, provides endoscopy solutions that enhance clinical outcomes and the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions in the United States and Israel. More Details


Snowflake Analysis

Imperfect balance sheet with limited growth.

Share Price & News

How has Motus GI Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: MOTS's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-5.0%

MOTS

-3.3%

US Medical Equipment

-3.3%

US Market


1 Year Return

-49.6%

MOTS

13.7%

US Medical Equipment

10.9%

US Market

Return vs Industry: MOTS underperformed the US Medical Equipment industry which returned 14.7% over the past year.

Return vs Market: MOTS underperformed the US Market which returned 13.1% over the past year.


Shareholder returns

MOTSIndustryMarket
7 Day-5.0%-3.3%-3.3%
30 Day-2.2%-2.5%-5.7%
90 Day-25.7%12.2%8.2%
1 Year-49.6%-49.6%14.7%13.7%13.4%10.9%
3 Yearn/a69.0%64.7%34.9%25.9%
5 Yearn/a140.9%122.6%84.6%63.8%

Price Volatility Vs. Market

How volatile is Motus GI Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Motus GI Holdings undervalued compared to its fair value and its price relative to the market?

3.21x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate MOTS's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate MOTS's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: MOTS is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: MOTS is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MOTS's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MOTS is good value based on its PB Ratio (3.2x) compared to the US Medical Equipment industry average (3.9x).


Next Steps

Future Growth

How is Motus GI Holdings forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

46.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MOTS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MOTS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MOTS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MOTS's revenue (68.1% per year) is forecast to grow faster than the US market (9.9% per year).

High Growth Revenue: MOTS's revenue (68.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if MOTS's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Motus GI Holdings performed over the past 5 years?

-26.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MOTS is currently unprofitable.

Growing Profit Margin: MOTS is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MOTS is unprofitable, and losses have increased over the past 5 years at a rate of 26.8% per year.

Accelerating Growth: Unable to compare MOTS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MOTS is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1.8%).


Return on Equity

High ROE: MOTS has a negative Return on Equity (-248.09%), as it is currently unprofitable.


Next Steps

Financial Health

How is Motus GI Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: MOTS's short term assets ($19.5M) exceed its short term liabilities ($10.3M).

Long Term Liabilities: MOTS's short term assets ($19.5M) exceed its long term liabilities ($2.3M).


Debt to Equity History and Analysis

Debt Level: MOTS's debt to equity ratio (89.7%) is considered high.

Reducing Debt: Insufficient data to determine if MOTS's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MOTS has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: MOTS has less than a year of cash runway if free cash flow continues to reduce at historical rates of 31.5% each year


Next Steps

Dividend

What is Motus GI Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate MOTS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MOTS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MOTS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MOTS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MOTS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.0yrs

Average management tenure


CEO

Tim Moran (48 yo)

1.92yrs

Tenure

US$1,659,356

Compensation

Mr. Timothy P. Moran, also known as Tim, has been the Chief Executive Officer and a Director of Motus GI Holdings Inc. since October 1, 2018. He served as President of the Americas at ConvaTec Group Plc si ...


CEO Compensation Analysis

Compensation vs Market: Tim's total compensation ($USD1.66M) is above average for companies of similar size in the US market ($USD601.34K).

Compensation vs Earnings: Tim's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Timothy Moran
CEO & Director1.92yrsUS$1.66m0.36%
$ 115.5k
Mark Pomeranz
President4.67yrsUS$1.09m0.089%
$ 28.1k
Andrew Taylor
Chief Financial Officer3.08yrsUS$719.23k0.044%
$ 14.0k
Scott Aldrich
Vice President of Marketing & Strategy0.67yrno datano data

2.0yrs

Average Tenure

49yo

Average Age

Experienced Management: MOTS's management team is not considered experienced ( 2 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Timothy Moran
CEO & Director1.92yrsUS$1.66m0.36%
$ 115.5k
Mark Pomeranz
President4.67yrsUS$1.09m0.089%
$ 28.1k
Shervin Korangy
Independent Director3.5yrsUS$104.08k0.085%
$ 26.9k
Samuel Nussbaum
Independent Director3.75yrsUS$106.58k0.054%
$ 17.0k
David Hochman
Independent Chairman of the Board3.75yrsUS$176.92k0.45%
$ 141.2k
Steven Edmundowicz
Member of Medical Advisory Boardno datano datano data
David Lieberman
Member of Medical Advisory Boardno datano datano data
Gary Pruden
Independent Director2.75yrsUS$104.08k0.21%
$ 65.2k
Darren Sherman
Independent Director3.75yrsUS$107.58k0.053%
$ 16.7k
Ian Gralnek
Member of Medical Advisory Boardno datano datano data
Brian Jacobson
Member of Medical Advisory Boardno datano datano data
Peter Siersema
Member of Medical Advisory Boardno datano datano data

3.8yrs

Average Tenure

48yo

Average Age

Experienced Board: MOTS's board of directors are considered experienced (3.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 11.4%.


Top Shareholders

Company Information

Motus GI Holdings, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Motus GI Holdings, Inc.
  • Ticker: MOTS
  • Exchange: NasdaqCM
  • Founded:
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$31.672m
  • Shares outstanding: 32.06m
  • Website: https://www.motusgi.com

Number of Employees


Location

  • Motus GI Holdings, Inc.
  • 1301 East Broward Boulevard
  • 3rd Floor
  • Fort Lauderdale
  • Florida
  • 33301
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MOTSNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDFeb 2018
7M4BST (Boerse-Stuttgart)YesCommon StockDEEURFeb 2018

Biography

Motus GI Holdings, Inc., medical technology company, provides endoscopy solutions that enhance clinical outcomes and the cost-efficiency associated with the diagnosis and management of gastrointestinal con ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/25 05:48
End of Day Share Price2020/09/24 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.